Saturday 17 October 2026 Export LFMD’s income statement to Excel — free account

LifeMD, Inc.

LFMD Healthcare Health Information Services

LifeMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $194.1 million, up 25.3% from fiscal 2024. In the quarter to June 2026, revenue fell 3.55%, EPS fell 166.7% and free cash flow fell 247.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

2.34 0.12 −4.88%

Follow LFMD

Alert me

Market cap: $118.6M
P/E: 0.0×
Fwd P/E: −17.9×
Dividend yield: —
F-score: 6/9
Altman Z: −0.02
Beneish M: −3.67
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.05

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	—	—	—	—	—	—	—	—	—	—

Insider Ownership 18.03%

Capital & Financial Ratios $m

Market Cap 118.58

Revenue 191.59

Net Income 0.43

Free Cash Flow (18.28)

Net Debt (25.14)

Current Ratio 0.90

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (17.90)

P/S ratio 0.58

P/B ratio 14.04

Past 5Y EPS Growth —

This Y EPS Growth (307.43%)

Next Y EPS Growth 82.37%

Next Y revenue growth 6.98%

Next 5Y EPS Growth (15.28%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 9.03%

10-year low 10-year high

P/B against its own 10 years 33.83%

10-year low 10-year high

EV/Sales against its own 10 years 9.69%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	33	33	37	25
Receivables	5	10	9	11
Inventory	3	3	3	3
Other	1	3	3	3
	43	52	52	42

	2023	2024	2025	Q'26
Payables	11	11	14	18
ST’ Debt	—	8	—	—
Other	—	—	—	—
	35	67	42	47

Compound Annual Growth %

	10y	5y	3y
Sales	66.03%	39.08%	17.69%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	62.44%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	50	47	—	—	—
’25	51	49	60	34	194
’24	44	51	53	7	155
’23	33	36	39	45	153
’22	29	30	31	28	119
’21	18	22	25	27	93
’20	4	9	11	13	37

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	0	(7)	—	—	—
’25	3	9	0	(3)	8
’24	5	5	7	1	18
’23	(3)	5	1	6	9
’22	(8)	(10)	(3)	(2)	(23)
’21	(9)	(11)	(7)	(6)	(33)
’20	1	(2)	(4)	(7)	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(9)	—	—	—
’25	1	6	(5)	(3)	(1)
’24	3	1	3	2	9
’23	(4)	2	(1)	3	0
’22	(14)	(13)	(5)	(4)	(36)
’21	(9)	(12)	(8)	(7)	(36)
’20	1	(2)	(5)	(7)	(13)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.20)	(0.16)	—	—	—
’25	0.01	(0.06)	(0.10)	0.41	0.25
’24	(0.19)	(0.19)	(0.14)	(0.02)	(0.53)
’23	(0.15)	(0.23)	(0.20)	(0.12)	(0.70)
’22	(0.46)	(0.45)	(0.26)	(0.40)	(1.57)
’21	(0.47)	(0.64)	(0.54)	(0.62)	(2.29)
’20	(0.25)	(0.30)	(1.65)	(2.56)	(4.44)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	0.50	1.05	0.60	0.40	0.50	3.70	1.72	1.14	3.99	3.18	Analyst estimates 2026–2028 Powerpack
	High	2.00	4.75	1.95	1.00	10.70	33.02	4.33	9.11	12.88	15.84
People
People	Employees	11	10	16	26	56	232	220	232	336	389
	Revenue/emp, $m	0.48	0.37	0.52	0.48	0.67	0.40	0.54	0.66	0.46	0.50
Income, $m
Income, $m	Revenue	5	4	8	12	37	93	119	153	155	194
	Gross margin, %	62.85	72.36	76.02	79.75	76.24	80.62	84.32	87.61	86.15	85.72
	EBT	(1)	(1)	(2)	(4)	(60)	(61)	(45)	(17)	(23)	(10)
	EBT margin, %	(23.35)	(37.46)	(28.96)	(29.28)	(161.96)	(66.02)	(37.52)	(11.41)	(14.58)	(5.25)
	Net income	(1)	(1)	(1)	(4)	(61)	(61)	(45)	(18)	(21)	16
	Depreciation	0	0	1	1	1	3	13	7	7	8
Per share, $
Per share, $	Revenue	0.78	0.44	0.94	1.26	2.61	3.44	3.84	4.50	3.76	4.30
	Earnings	(0.17)	(0.15)	(0.10)	(0.35)	(4.44)	(2.29)	(1.57)	(0.70)	(0.53)	0.25
	Cash flow	(0.06)	(0.10)	(0.10)	0.03	(0.85)	(1.22)	(0.74)	0.26	0.43	0.18
	Capex	0.00	0.00	(0.01)	0.00	(0.03)	(0.13)	(0.42)	(0.26)	(0.20)	(0.21)
	Free cash flow	(0.06)	(0.10)	(0.11)	0.03	(0.88)	(1.35)	(1.16)	0.00	0.23	(0.03)
	Book value	(0.05)	0.07	0.09	(0.11)	(0.06)	0.96	(0.24)	0.16	(0.18)	0.51
	Shares, m	7	8	9	10	14	27	31	34	41	45
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.12
	P/S	1.53	4.08	0.74	0.48	2.50	1.13	0.49	1.87	1.32	0.79
	P/B	0.00	24.13	7.55	0.00	0.00	4.81	0.00	51.35	0.00	6.65
	EV/Sales	1.52	4.07	0.73	0.46	2.28	0.70	0.49	1.78	1.22	0.68
	EV/FCF	(19.50)	(18.34)	(6.70)	22.58	(6.76)	(1.78)	(1.64)	3,127.18	20.37	(106.73)
Cash, $m
Cash, $m	Operating cash flow	0	(1)	(1)	0	(12)	(33)	(23)	9	18	8
	Capex	—	—	0	—	0	(3)	(13)	(9)	(8)	(10)
	Free cash flow	0	(1)	(1)	0	(13)	(36)	(36)	0	9	(1)
Balance, $m
Balance, $m	Working capital	0	1	0	(1)	(2)	22	(20)	8	(15)	10
	Total debt	0	0	0	1	1	2	4	18	18	—
	Net debt	0	0	0	0	(8)	(39)	0	(15)	(14)	(37)
	Shareholders’ equity	0	1	1	(1)	(1)	26	(7)	6	(8)	23
Returns, %
Returns, %	ROA	(178.87)	(117.45)	(63.96)	(103.50)	(752.12)	(195.08)	(128.70)	(56.34)	(36.43)	15.35
	ROIC	0.00	(118.32)	(144.88)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	1,225.79	(923.78)	(172.03)	2,027.27	2,260.22	(716.97)	(988.99)	751.79	2,465.96	144.18

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SPOK Spok Holdings, Inc.	$224.5M	17.7×	16.2×	−1.89% (below 0%: shrinking)	−9.09% (below 0%: shrinking)	−2.00% (below 0%: shrinking)	80.47%	15.50%	Compare
AMWL American Well Corporation	$210.6M	— (loss-making)	— (loss-making)	−26.59% (below 0%: shrinking)	n/m	+266.38% (above 0%: growing)	52.95%	(18.36%)	Compare
SY So-Young International Inc. Sponsored ADR	$198.9M	— (loss-making)	12.8×	+40.84% (above 0%: growing)	n/m	−798.37% (below 0%: shrinking)	44.11%	(8.64%)	Compare
OPRX OptimizeRx Corp.	$166.7M	35.4×	23.0×	−29.77% (below 0%: shrinking)	n/m	+89.86% (above 0%: growing)	76.51%	(0.43%)	Compare
DH Definitive Healthcare Corp.	$144.3M	— (loss-making)	— (loss-making)	−9.14% (below 0%: shrinking)	n/m	+21.44% (above 0%: growing)	73.45%	(12.23%)	Compare
HCAT Health Catalyst, Inc.	$135.5M	— (loss-making)	— (loss-making)	−12.68% (below 0%: shrinking)	n/m	+64.26% (above 0%: growing)	49.46%	(51.75%)	Compare
LFMD LifeMD, Inc.	$118.6M	— (loss-making)	— (loss-making)	−3.55% (below 0%: shrinking)	n/m	−247.52% (below 0%: shrinking)	88.82%	(15.08%)
CCLD CareCloud, Inc.	$82.0M	26.4×	12.5×	+16.45% (above 0%: growing)	n/m	+6.15% (above 0%: growing)	45.24%	5.84%	Compare
DRIO DarioHealth Corp.	$50.3M	— (loss-making)	— (loss-making)	−3.58% (below 0%: shrinking)	n/m	−0.74% (below 0%: shrinking)	61.66%	(125.15%)	Compare
Median of peers	$155.5M	26.4×	14.5×	−6.36%	—	+13.80%	57.31%	(10.43%)

All 51 Health Information Services stocks →

LifeMD, Inc. (LFMD) key facts

Strength: LifeMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $194.1 million, up 25.3% from fiscal 2024.
LifeMD, Inc. (LFMD) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LFMD traded at $2.34, a market capitalization of $118.6 million.
Return on equity was 144.2% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is −0.02 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.